Harmonised BMD surveillance guidance for young cancer survivors released
An international expert group has published recommendations for the monitoring of bone mineral density in child, adolescent and young adult survivors of cancer.
Knowledge gaps make teens with endocrine disorders unready for transition to adult clinic
Researchers find that teenagers with endocrine disorders often have gaps in their knowledge of their condition and how to manage it, making them poorly prepared for transition to adult clinic.
Vosoritide ‘effective’ for increasing growth in children with achondroplasia
The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Factors predicting loss to follow-up identified for children with chronic endocrine conditions
Factors including age at diagnosis and the specific disease influence the likelihood of children with chronic endocrine conditions being lost to follow-up, show French study findings.
Research focus: ‘Health not height’ – Trial results for a targeted treatment for children with achondroplasia
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosoritide in children with achondroplasia.
C-type natriuretic peptide analogue increases growth velocity in children with achondroplasia
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.
Screening protocol proposed for paediatric SDHB-linked tumours
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
Monoclonal antibody offers alternative treatment for X-linked hypophosphataemic rickets
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
Benefits of asfotase alfa in infants with severe hypophosphatasia sustained in long term
Researchers report sustained improvements in skeletal mineralisation, along with other benefits including improved growth and respiratory function, in children with life-threatening perinatal or infantile hypophosphatasia during 7 years of treatment with asfotase alfa.
Higher vitamin D supplementation doses needed for effectiveness in children
Higher doses of vitamin D3 than currently recommended may be needed to achieve vitamin D sufficiency in schoolchildren living at northern latitudes, show the results of a randomised trial.